date:Sep 28, 2018
tion of precision medicine, a strategy not often embraced in immune diseases, which he said have been dominated by a more nuclear approach using steroids or general immunosuppressants.
The company's also testing Dupixent in combination with Aimmune's peanut allergy treatment. But its approach to allergy doesn't stop there.
Can we target the allergen itself? Jamie Orengo, Regeneron's director of immunology and inflammation, said in an interview. We try to develop antibodies that are specific fo